Table 4.
Individual coefficients of the variables included in the Cox regression.
| Covariates | HR | CI (HR) 95% | p-Value |
|---|---|---|---|
| ECOG 1 | 3.247 | 1.606–6.562 | 0.001 |
| Stage IV | 6.539 | 1.983–21.565 | 0.002 |
| TI locally advanced | - | - | 0.001 |
| TI first line | 5.063 | 1.108–23.126 | 0.036 |
| TI second line and more | 12.840 | 2.962–55.656 | 0.001 |
| Durvalumab | - | - | 0.001 |
| Nivolumab | 3.336 | 0.302–36.831 | 0.325 |
| Pembrolizumab | 5.668 | 1.266–25.376 | 0.023 |
| Atezolizumab | 15.635 | 3.543–68.922 | <0.001 |
| Complete response | - | - | <0.001 |
| Partial response | 4.582 | 0.534–39.348 | 0.165 |
| Stable disease | 8.384 | 1.026–68.509 | 0.047 |
| Progressive disease | 37.880 | 4.830–297.063 | 0.001 |
| Not evaluable | 377.216 | 33.191–4287.125 | <0.001 |
| High LDH > 214 U/L | 2.262 | 1.124–4.551 | 0.022 |
| NK CD16- PD-1+ (>9.5) | 2.052 | 0.980–4.295 | 0.056 |
ECOG: Eastern Cooperative Oncology Group; TI: Treatment indication; LDH: Lactate dehydrogenase.